

Bibliografía

1. Kirwan JR, Hewlett SE, Heiberg T, Hughes RA, Carr M, Hehir M, *et al.* Incorporating the patient perspective into outcome assessment in rheumatoid arthritis-progress at OMERACT 7. *J Rheumatol.* 2005;32:2250-6.
2. Kirwan JR, Tugwell PS. Overview of the patient perspective at OMERACT 10-conceptualizing methods for developing patient-reported outcomes. *J Rheumatol.* 2011;38:1699-701.
3. Committee for Medicinal Products for Human Use, European Medicines Agency. Guideline on clinical investigation of medicinal products other than NSAIDs for treatment of rheumatoid arthritis. [Internet]. European Medicines Agency; 2015. [Fecha de acceso: 14 Nov 2016]. Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/06/WC500187583.pdf
4. Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, *et al.* Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. *Arthritis Rheumatol.* 2015;67:1424-37.
5. Strand V, Kosinski M, Chen CI, Joseph G, Rendas-Baum R, Graham NM, *et al.* Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. *Arthritis Res Ther.* 2016;18:198.
6. Fleischmann R, van Adelsberg J, Lin Y, Castelar-Pinheiro GD, Brzezicki J, Hrycaj P, *et al.* Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. *Arthritis Rheumatol.* 2017;69:277-90.
7. Strand V, Reaney M, Chen CI, Proudfoot CWJ, Guillonneau S, Bauer D, *et al.* Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/ intolerance to tumour necrosis factor inhibitors. *RMD Open.* 2017;3:e000416.
8. Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NM, *et al.* Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. *Ann Rheum Dis.* 2017;76:840-7.
9. Strand V, Gossec L, Proudfoot CWJ, Chen CI, Reaney M, Guillonneau S. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis. *Arthritis Res Ther.* 2018;20:129.
10. Choy EHS, Calabrese LH. Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis. *Rheumatology (Oxford).* 2018;57:1885-95.
11. Brenn D, Richter F, Schaible HG. Sensitization of unmyelinated sensory fibers of the joint nerve to mechanical stimuli by interleukin-6 in the rat: an inflammatory mechanism of joint pain. *Arthritis Rheum.* 2007;56:351-9.
12. Von Banchet GS, Kiehl M, Schaible H. Acute and long-term effects of IL-6 on cultured dorsal root ganglion neurones from adult rat. *J Neurochem.* 2005;94:238-48.
13. Nikolaus S, Bode C, Taal E, van de Laar MA. Fatigue and factors related to fatigue in rheumatoid arthritis: a systematic review. *Arthritis Care Res (Hoboken).* 2013;65:1128-46.
14. Girotti M, Donegan JJ, Morilak DA. Influence of hypothalamic IL-6/gp130 receptor signaling on the HPA axis response to chronic stress. *Psychoneuroendocrinology.* 2013;38:1158-69.
15. Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. *J Clin Endocrinol Metab.* 1993;77:1690-4.
16. Vgontzas AN, Papanicolaou DA, Bixler EO, Litsikas A, Zachman K, Kales A, *et al.* Circadian Interleukin-6 Secretion and Quantity and Depth of Sleep. *J Clin Endocrinol Metab.* 1999;84:2603-7.
17. Vgontzas AN, Bixler EO, Lin HM, Prolo P, Trakada G, Chrousos GP. IL-6 and its circadian secretion in humans. *Neuroimmunomodulation.* 2005;12:131-40.
18. Matcham F, Rayner L, Steer S, Hotopf M. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. *Rheumatology.* 2013;52:2136-48.
19. Hodes GE, Pfau ML, Leboeuf M, Golden SA, Christoffel DJ, Bregman D, *et al.* Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress. *Proc Natl Acad Sci U S A.* 2014;111:16136-41.
20. Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. *Cytokine.* 1997;11:853-8.
21. Bonaccorso S, Puzella A, Marino V, Pasquini M, Biondi M, Artini M, *et al.* Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. *Psychiatry Res.* 2001;105:45-55.
22. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, *et al.* Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. *Lancet.* 2008;371:987-97.
23. Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, *et al.* Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results

- from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. *Arthritis Rheum*. 2011;63:609-21.
24. Almeida C, Choy EH, Hewlett S, Kirwan JR, Cramp F, Chalder T, *et al*. Biologic interventions for fatigue in rheumatoid arthritis. *Cochrane Database Syst Rev*. 2016:CD008334.
 25. Atzeni F, Nucera V, Masala IF, Sarzi-Puttini P, Bonitta G. Il-6 Involvement in pain, fatigue and mood disorders in rheumatoid arthritis and the effects of Il-6 inhibitor sarilumab. *Pharmacological Research*. 2019;149:104402.
 26. Strand V, Mshid J, Kimura T, Boyapati A, St John G, Wei W. High Baseline Serum IL-6 Predicts Increased Sarilumab Treatment Response for Patient Reported Symptoms and Health-Related Quality of Life Among Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate. [Abstract 1378]. [Internet]. En: 2019 ACR/ARP Annual Meeting. 2019. [Fecha de acceso: 7 Oct 2019]. Disponible en: <https://acrabstracts.org/abstract/high-baseline-serum-il-6-predicts-increased-sarilumab-treatment-response-for-patient-reported-symptoms-and-health-related-quality-of-life-among-rheumatoid-arthritis-patients-with-inadequate-response-t/>
 27. Strand V, Boklage S, Mangan E, Reaney, Iglesias-Rodríguez M, Kimura T. Patient-reported outcomes with sarilumab in patients with rheumatoid arthritis are similar regardless of primary or secondary failure with tumour necrosis factor inhibitors. *Ann Rheum Dis*. 2018;77:615-6.
 28. Curtis J, Aletaha D, Burmester G, Ford K, van Hoogstraten H, Leher H, Thangavelu K, Bykerk V. Low Probability of Clinical Worsening Following Switching Biologic DMARD in Patients with RA and Partial Response to Adalimumab. [Abstract 1387]. [Internet]. En: 2019 ACR/ARP Annual Meeting. 2019. [Fecha de acceso: 18 Nov 2019]. <https://acrabstracts.org/abstract/low-probability-of-clinical-worsening-following-switching-biologic-dmard-in-patients-with-ra-and-partial-response-to-adalimumab/>
 29. Bykerk V, Wei W, Boklage S, Kimura T, Fiore S, St John G. Impact of Sarilumab on Unacceptable Pain and Inflammation Control in Moderately-to-Severely Active Rheumatoid Arthritis (RA) Patients in 3 Phase 3 Studies. [Abstract 1393]. [Internet]. En: 2018 ACR/ARHP Annual Meeting. 2018. [Fecha de acceso: 7 Oct 2019]. Disponible en: <https://acrabstracts.org/abstract/impact-of-sarilumab-on-unacceptable-pain-and-inflammation-control-in-moderately-to-severely-active-rheumatoid-arthritis-ra-patients-in-3-phase-3-studies/>
 30. Gossec L, Boklage S, St. John G, van Hoogstraten H, Kimura T. Pain Is Improved in Around 50% of Patients and Fatigue in 40% of Patients with Rheumatoid Arthritis Treated with Sarilumab in the Target, Mobility and Monarch Trials. [Abstract 1523]. [Internet]. En: 2018 ACR/ARHP Annual Meeting. [Fecha de acceso: 7 Oct 2018]. Disponible en: <https://acrabstracts.org/abstract/pain-is-improved-in-around-50-of-patients-and-fatigue-in-40-of-patients-with-rheumatoid-arthritis-treated-with-sarilumab-in-the-target-mobility-and-monarch-trials/>
 31. Strand V, Carpinella CM, Lee LK, Boklage S, Reaney M. The Impact of Rheumatoid Arthritis on Patient-Reported Outcomes: Comparison between Sarilumab Clinical Trials and Real-World Patient Data. [Abstract 2548]. [Internet]. En: 2018 ACR/ARHP Annual Meeting. 2018. [Fecha de acceso: 8 Oct 2018]. Disponible en: <https://acrabstracts.org/abstract/the-impact-of-rheumatoid-arthritis-on-patient-reported-outcomes-comparison-between-sarilumab-clinical-trials-and-real-world-patient-data/>
 32. Tornero Molina J. Encaje terapéutico de sarilumab en el tratamiento de la artritis reumatoide. *Reumatol Clin Supl*. 2018;14:70-7.
 33. Strand V, Gossec L, Proudfoot C, Chen C, Reaney M, Guilloneau S, *et al*. Patient reported benefits of sarilumab monotherapy versus adalimumab monotherapy in adult patients with active rheumatoid arthritis. *Ann Rheum Dis*. 2017;76(Suppl 2):94.